News

Gloucester has reported that it will discuss the New Drug Application for romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL) at the Oncologic Drugs Advisory Committee (ODAC)

GeoPharma has reported a decrease in revenues for the first quarter of FY2010, to $5.2m, compared to $6.4m for the same period of FY2009. Overall Gross Profits from

AEterna Zentaris has reported phase 3 results for its North American efficacy trial – Z-033 and the safety trial – Z-041 in benign prostatic hyperplasia (BPH), with its

CSL Behring has announced that Helixate FS, Antihemophilic Factor (Recombinant), has been approved by the FDA. It is for routine prophylaxis in children with hemophilia A who are

SonoSite has acquired CardioDynamics. Under the terms of the agreement, CardioDynamics will become a wholly-owned subsidiary of SonoSite and CardioDynamics’ shareholders will receive $1.35 per share in cash.

NeuroSearch has signed a drug discovery and drug development agreement with Janssen Pharmaceutica (Janssen). As per the agreement, NeuroSearch and Janssen will collaborate to discover, develop and commercialise

Amgen has reported positive top-line results from a phase 3 trial evaluating Vectibix (panitumumab) in combination with Folfiri (an irinotecan-based chemotherapy) as a second-line treatment in 1,186 patients

Novartis has received FDA approval for Extavia (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from the company. Extavia is approved by

Eli Lilly has reported that the US District Court for the Eastern District of Michigan has granted a motion by Sun Pharmaceuticals for partial summary judgment. Reportedly, the